Search - tctmd.com

Displaying 1 - 20 of 58

Sort: Relevancy | Date

News Opinion CV Team Dispatch

November 2025 Dispatch for the CV Team

L.A. McKeown

November 24, 2025

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Opinion CV Team Dispatch

March 2025 Dispatch for the CV Team

L.A. McKeown

March 21, 2025

News Conference News THT 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

Todd Neale

February 12, 2025

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

L.A. McKeown

December 20, 2024

News Features

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

Todd Neale

November 13, 2024

News Opinion CV Team Dispatch

October 2024 Dispatch for the CV Team

L.A. McKeown

October 25, 2024

News Daily News

AHA Statement Outlines Cardiac Contributions to Brain Health

L.A. McKeown

October 11, 2024

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

L.A. McKeown

September 01, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

News Daily News

Statins Might Help in HFpEF—Even in the Absence of ASCVD

Todd Neale

May 01, 2024

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

News Opinion CV Team Dispatch

March 2024 Dispatch for the CV Team

L.A. McKeown

March 01, 2024

News Opinion CV Team Dispatch

January 2024 Dispatch for the CV Team

L.A. McKeown

January 01, 2024

Advertisement

November 2025 Dispatch for the CV Team

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

March 2025 Dispatch for the CV Team

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

December 2024 Dispatch for the CV Team

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

October 2024 Dispatch for the CV Team

AHA Statement Outlines Cardiac Contributions to Brain Health

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

September 2024 Dispatch for the CV Team

August 2024 Dispatch for the CV Team

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Statins Might Help in HFpEF—Even in the Absence of ASCVD

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

March 2024 Dispatch for the CV Team

January 2024 Dispatch for the CV Team

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content